BlackThorn Therapeutics Secures $76 Million Series B Financing to Advance AI-Powered Data Platform for Neuropsychiatric Drug Development

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 13, U.S. local time, biopharmaceutical company BlackThorn Therapeutics completed a $76 million Series B financing round. The funds raised will be used to support the development of the company’s data analytics platform and the research and development of psychiatric medications.

It is reported that this round of financing was jointly invested by Polaris Partners, Premier Partners, Vertex Ventures HC, Alexandria Venture Investments, Arch Venture Partners, GV, and others.

BlackThorn Therapeutics, founded in 2013 and headquartered in California, USA, is a clinical-stage biopharmaceutical company focused on the treatment of psychiatric disorders.

BlackThorn Therapeutics, Inc. has developed emerging artificial intelligence technologies for targeted treatment of brain disorders. PathFinder is the company’s core technology platform, built on cloud computing infrastructure, enabling high-speed, large-scale collection, integration, and analysis of multimodal data.

BlackThorn Therapeutics leverages data-driven approaches to analyze the core issues of mental disorders, integrates data with human brain analysis to identify biomarkers, and develops corresponding drugs for targeted treatment of different categories of mental illnesses.

This analytical approach not only visualizes the human brain’s nervous system, enabling researchers to identify issues more intuitively and develop more targeted therapeutics, but also mitigates the impact of currently available broad-spectrum psychotropic drugs on other brain components, thereby reducing post-administration side effects.

Polaris Partners, founded in 1996 and headquartered in Massachusetts, USA, is a venture capital firm specializing in early- and late-stage investments in biotechnology startups, having completed 506 investments to date.

Premier Partners, established in 2005 and headquartered in Seoul, South Korea, is a private equity firm specializing in investing in startups across various stages of development in sectors such as finance. To date, it has completed 12 investments.

Vertex Ventures HC, headquartered in California, USA, is a venture capital firm focused on early-stage investments in startups within the biopharmaceuticals, medical devices, and digital health sectors. To date, it has completed 20 investments.

Alexandria Venture Investments, established in 1996 in California, USA, is a venture capital firm that has been dedicated to investing in the early and late-stage development of healthcare startups since its inception, with 68 investments completed to date.

Arch Venture Partners, established in 1986 in Illinois, USA, is a venture capital firm primarily focused on startups in the healthcare and clean energy sectors. It has invested in over 120 companies to date, with total assets under management amounting to $1.9 billion.

GV (Google Ventures) is the investment arm of Google, established in March 2008. Leveraging its strengths, Google aims to support innovative and promising technology companies through early-stage investments across multiple sectors, including consumer internet, software, clean technology, biotechnology, healthcare, and other fields.

(Compiled by Liu Yujing)